memo - Magazine of European Medical Oncology

, Volume 1, Issue 2, pp 61–65

Adjuvant chemotherapy in stage IB non-small cell lung cancer: if, when, how?

Authors

    • Medical Oncology DepartmentInstitute of Oncology Bucharest
Short review

DOI: 10.1007/s12254-008-0015-4

Cite this article as:
Dediu, M. memo (2008) 1: 61. doi:10.1007/s12254-008-0015-4

Summary

Adjuvant chemotherapy is established as a standard of care for resectable non-small cell lung cancer. However, this indication remains controversial for the stage IB as the results of the randomized trials and meta-analysis are obscuring on this issue. Moreover, the updated international guidelines do not prescribe the regular use of this strategy in stage IB. The aim of this paper is to review the current evidences regarding the benefit of adjuvant CT in this setting, and to provide clinical hints, which can lend a helping hand to the clinicians and their patients to take the right decision in this particular scenario.

Keywords

Adjuvant chemotherapyStage IBRisk factorsNSCLC

Copyright information

© Springer-Verlag 2008